BALAXI PHARMACEUTICALS Financial Statement Analysis
|
||
|
The Revenues of BALAXI PHARMACEUTICALS have decreased by -28.28% YoY .
The Earnings Per Share (EPS) of BALAXI PHARMACEUTICALS has increased by Positive YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
BALAXI PHARMACEUTICALS Last 5 Annual Financial Results
[NSE : BALAXI]
| Consolidated | Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 |
|---|---|---|---|---|---|
| Revenues | ₹241 Cr | ₹336 Cr | ₹279 Cr | ₹231 Cr | ₹46 Cr |
| Expenses | ₹197 Cr | ₹279 Cr | ₹229 Cr | ₹189 Cr | ₹37 Cr |
| Operating Profit (Excl OI) | ₹45 Cr | ₹57 Cr | ₹51 Cr | ₹43 Cr | ₹8.25 Cr |
| Other Income | ₹0.63 Cr | ₹2.64 Cr | ₹4.97 Cr | ₹2.23 Cr | ₹0.60 Cr |
| Interest | ₹2.77 Cr | ₹1.38 Cr | ₹0.76 Cr | ₹0.28 Cr | ₹0.05 Cr |
| Depreciation | ₹2.10 Cr | ₹1.75 Cr | ₹0.51 Cr | ₹0.30 Cr | ₹0.01 Cr |
| Profit Before Tax | ₹2.02 Cr | ₹57 Cr | ₹55 Cr | ₹44 Cr | ₹8.79 Cr |
| Profit After Tax | ₹-2.39 Cr | ₹46 Cr | ₹48 Cr | ₹38 Cr | ₹6.10 Cr |
| Consolidated Net Profit | ₹-7.31 Cr | ₹52 Cr | ₹48 Cr | ₹37 Cr | ₹6.13 Cr |
| Earnings Per Share (Rs) | ₹5.01 | ₹-6.70 | ₹50.82 | ₹48.18 | ₹37.23 |
| PAT Margin (%) | 8.57 | -0.99 | 13.66 | 17.06 | 16.49 |
| ROE(%) | 11.68 | -1.29 | 32.17 | 53.50 | 82.26 |
| ROCE(%) | 13.01 | 2.31 | 37.46 | 59.62 | 92.56 |
| Total Debt/Equity(x) | 0.22 | 0.09 | 0.07 | 0.03 | 0.06 |
Key Financials |
||
| Market Cap | : | ₹ 253.1 Cr |
| Revenue (TTM) | : | ₹ 297.7 Cr |
| Net Profit(TTM) | : | ₹ 18.9 Cr |
| EPS (TTM) | : | ₹ 3.4 |
| P/E (TTM) | : | 13.4 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| BALAXI PHARMACEUTICALS | -2% | -4.2% | -57.5% |
| ADANI ENTERPRISES | -3.5% | -11.9% | -25.9% |
| REDINGTON | -1% | -16.3% | 15.7% |
| MMTC | -5.2% | -8% | -39.6% |
| HONASA CONSUMER | -2.4% | 10.6% | -42.6% |
| LLOYDS ENTERPRISES | -1.3% | -5.7% | 72.3% |
| ENTERO HEALTHCARE SOLUTIONS | -3.8% | -7.6% | -8.1% |
| OPTIEMUS INFRACOM | -5.3% | -6.1% | -6.1% |
| POLO QUEEN INDUSTRIAL & FINTECH | 8.3% | -12.9% | 0.8% |
BALAXI PHARMACEUTICALS Revenues
[NSE : BALAXI]
| Y-o-Y | -28.28 % |
| 5 Yr CAGR | 51.64 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2025 | ₹241 Cr | -28.28 | |
| Mar2024 | ₹336 Cr | 20.42 | |
| Mar2023 | ₹279 Cr | 20.77 | |
| Mar2022 | ₹231 Cr | 406.94 | |
| Mar2021 | ₹46 Cr | - | |
BALAXI PHARMACEUTICALS Operating Profit
[NSE : BALAXI]
| Y-o-Y | -22.42 % |
| 5 Yr CAGR | 52.41 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2025 | ₹45 Cr | -22.42 | |
| Mar2024 | ₹57 Cr | 12.97 | |
| Mar2023 | ₹51 Cr | 19.08 | |
| Mar2022 | ₹43 Cr | 417.06 | |
| Mar2021 | ₹8.25 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | 8.14 % |
| 5 Yr CAGR | 0.51 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2025 | 18.46% | 8.14 | |
| Mar2024 | 17.07% | -6.16 | |
| Mar2023 | 18.19% | -1.41 | |
| Mar2022 | 18.45% | 1.99 | |
| Mar2021 | 18.09% | - | |
BALAXI PHARMACEUTICALS Profit After Tax
[NSE : BALAXI]
| Y-o-Y | Negative |
| 5 Yr CAGR | Negative |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2025 | ₹-7.31 Cr | Negative | |
| Mar2024 | ₹52 Cr | 7.39 | |
| Mar2023 | ₹48 Cr | 29.41 | |
| Mar2022 | ₹37 Cr | 507.51 | |
| Mar2021 | ₹6.13 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | Positive |
| 5 Yr CAGR | -15.09 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2025 | 8.57 % | Positive | |
| Mar2024 | -0.99 % | Negative | |
| Mar2023 | 13.66 % | -19.93 | |
| Mar2022 | 17.06 % | 3.46 | |
| Mar2021 | 16.49 % | - | |
BALAXI PHARMACEUTICALS Earnings Per Share (EPS)
[NSE : BALAXI]
| Y-o-Y | Positive |
| 5 Yr CAGR | -39.43 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2025 | ₹5.01 | Positive | |
| Mar2024 | ₹-6.70 | Negative | |
| Mar2023 | ₹51 | 5.48 | |
| Mar2022 | ₹48 | 29.41 | |
| Mar2021 | ₹37 | - | |
BALAXI PHARMACEUTICALS Return on Capital Employed (ROCE)
[NSE : BALAXI]
| Y-o-Y | 463.20 % |
| 5 Yr CAGR | -38.77 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2025 | 13.01% | 463.20 | |
| Mar2024 | 2.31% | -93.83 | |
| Mar2023 | 37.46% | -37.17 | |
| Mar2022 | 59.62% | -35.59 | |
| Mar2021 | 92.56% | - | |
BALAXI PHARMACEUTICALS Share Price vs Sensex
| Current Share Price | : | ₹45.9 |
| Current MarketCap | : | ₹ 253.1 Cr |
| Updated EOD on | : | Aug 29,2025 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| BALAXI PHARMACEUTICALS | -2% |
-4.2% |
-57.5% |
| SENSEX | -2.7% |
-1.3% |
-2.3% |
BALAXI PHARMACEUTICALS related INDICES
No BSE index found!
No NSE index found
You may also like the below Video Courses
FAQ about BALAXI PHARMACEUTICALS Financials
How the annual revenues of BALAXI PHARMACEUTICALS have changed ?
The Revenues of BALAXI PHARMACEUTICALS have decreased by -28.28% YoY .
How the Earnings per Share (EPS) of BALAXI PHARMACEUTICALS have changed?
The Earnings Per Share (EPS) of BALAXI PHARMACEUTICALS has increased by Positive YoY .
Check out Intrinsic Value of Peers of BALAXI PHARMACEUTICALS
|
Intrinsic Value of ADANI ENTERPRISES LTD Intrinsic Value of REDINGTON LTD Intrinsic Value of MMTC LTD Intrinsic Value of HONASA CONSUMER LTD Intrinsic Value of LLOYDS ENTERPRISES LTD |
Compare Stock Analytics of Peers of BALAXI PHARMACEUTICALS
ADANI ENTERPRISES LTD vs REDINGTON LTD vs MMTC LTD
HONASA CONSUMER LTD vs LLOYDS ENTERPRISES LTD vs
ADANI ENTERPRISES LTD vs REDINGTON LTD vs MMTC LTD
HONASA CONSUMER LTD vs LLOYDS ENTERPRISES LTD vs
